Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.42 USD | +5.22% | +7.56% | -66.20% |
28/03 | CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
05/03 | Top Midday Gainers | MT |
Sales 2024 * | 59.17M 4.93B | Sales 2025 * | 88.09M 7.34B | Capitalization | 31.43M 2.62B |
---|---|---|---|---|---|
Net income 2024 * | - 0 | Net income 2025 * | 11M 917M | EV / Sales 2024 * | 0.53 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.36 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
7.12
x | Employees | 176 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 50.99% |
1 day | +5.22% | ||
1 week | +7.56% | ||
Current month | -32.96% | ||
1 month | -19.33% | ||
3 months | -65.43% | ||
6 months | -27.11% | ||
Current year | -66.20% |
Managers | Title | Age | Since |
---|---|---|---|
Wei Wu He
CEO | Chief Executive Officer | 59 | 02/19/02 |
Wei Zhang
DFI | Director of Finance/CFO | 64 | 01/18/01 |
Chun Hua Wang
COO | Chief Operating Officer | 52 | 01/17/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Wei Wu He
CEO | Chief Executive Officer | 59 | 02/19/02 |
Yue Wu
BRD | Director/Board Member | 62 | 01/13/01 |
Zhen Bo Su
BRD | Director/Board Member | 48 | 21/23/21 |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 2.42 | +5.22% | 3,669 |
25/24/25 | 2.3 | -5.74% | 27,765 |
24/24/24 | 2.44 | -2.79% | 9,123 |
23/24/23 | 2.51 | +3.29% | 13,047 |
22/24/22 | 2.43 | +8.00% | 13,103 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-66.20% | 31.43M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- CASI Stock